Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Abrdn Physical Platinum Shares ETF (PPLT) vs Zoetis Inc (ZTS) Price & Performance

Abrdn Physical Platinum Shares ETFTrade
Zoetis IncTrade

Price performance (Past 24H)

Key statistics

Abrdn Physical Platinum Shares ETF vs Zoetis Inc — how do they compare? Abrdn Physical Platinum Shares ETF trades at $17.03, while Zoetis Inc trades at $73.95 (market cap $30.40B). The key difference: Zoetis Inc pays a 2.88% dividend while Abrdn Physical Platinum Shares ETF pays none, and Abrdn Physical Platinum Shares ETF is trading nearer its 52-week high, Zoetis Inc nearer its low. Which is the better fit depends on your goals.

PPLTZTS
Sector
Commodities - Metals/AgricultureHealth
52-Week High
$25.23$150.61
52-Week Low
$12.38$71.91
Market Cap
$30.40B
Enterprise Value
$37.96B
Dividend Yield
2.88%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Abrdn Physical Platinum Shares ETF

PPLT (abrdn Platinum ETF Trust) trades at $16.46, down 0.24% with a bullish technical signal from moving averages. The ETF tracks physical platinum prices, which have lagged behind gold and silver's recent rally. Recent news highlights platinum's potential catch-up trade opportunity as price ratios suggest potential mean reversion. Technical indicators show mixed signals with neutral oscillators but strong trend strength from ADX.

The outlook suggests potential upside as platinum seeks to close its performance gap with other precious metals. Key risks include commodity price volatility and macroeconomic factors affecting industrial demand. Investment opportunity lies in platinum's historical tendency for mean reversion and its dual role as both precious metal and industrial commodity.

Zoetis Inc

Zoetis (ZTS) trades at $73.60, down 2.92% amid bearish technical signals and mixed earnings. The stock faces pressure from weakening U.S. companion animal sales and competitive headwinds, though profitability remains strong with 71.67% gross margins and 27.69% net income margin. Recent Q2 2026 earnings beat estimates but revenue missed, prompting a guidance cut. Analyst consensus is divided with 45% Buy ratings and a $93.40 price target, suggesting 27% upside from current levels.

The outlook balances valuation appeal (P/E of 12) against near-term operational challenges. Investment opportunity lies in market dominance and robust cash flow generation, while risks include sustained pet health demand softness and competitive pricing pressure. The stock trades near support at $73, with institutional sentiment mixed amid recent portfolio adjustments.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Abrdn Physical Platinum Shares ETF

PPLT is a physically-backed ETF designed to track the spot price of platinum, less the Trust's expenses. It holds physical platinum bullion in secure vaults, providing investors with a liquid and cost-effective way to access the platinum market without the logistical challenges of direct ownership.

Read more on PPLT

About Zoetis Inc

Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns slightly less than half of total revenue from production animals (cattle, pigs, poultry, and so on), and more than half from companion animal (dogs, horses, cats) products make up the other half. Its U.S. business is heavily skewed toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.

Read more on ZTS